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ABSTRACT 
 
 Melanoma is the least common of skin cancers but is the most aggressive 
subset. Arising from the melanocytes found in the epidermal-dermal junction of 
the skin, the disease has frequently been linked to increased exposure to UV 
irradiation in addition to significant genetic influences. Melanoma can be cured 
with surgical intervention if the lesion is detected at an early stage. However, 
prognosis is poor after melanoma has metastasized to other organs and there 
are few treatment options available outside of chemotherapy. Little is known 
about the molecular basis for the biological behavior of melanoma, making its 
clinical course somewhat unpredictable and rational treatment prioritization 
extremely difficult.  
 Biomarkers are prognostic factors that mimic the biological tendencies of a 
tumor. They can be physical markers or molecular fingerprints. Identification of 
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biomarkers in melanoma will allow clinicians and researchers to better predict the 
behavior of melanocytic tumors, thus allowing for a more optimal prioritization of 
treatment for each individual affected by this disease. Much research has gone 
into developing biomarkers related to genetic alterations associated with 
melanoma onset and progression; however independent confirmatory tests or 
data from clinical trials are still needed to validate the research. Recent studies 
have explored the relationship between cancer and the host’s immune response. 
Cancer cells are known to secrete cytokines and growth factors that influence its 
own aggressiveness. Moreover, the discovery of tumor associated antigens 
serve as more evidence that there is an immune response to cancer and hold 
promising clinical therapies for the future. 
 We investigated the RNA expression of two genes in efforts to better 
predict melanoma progression: IL-6 and IGFBP3. IL-6 is a cytokine of the 
immune system that, when activated, stimulates the stromal tissue surrounding 
the point of injury and activates other inflammatory cells. IGFBP3 is a member of 
the IGFBP superfamily and is speculated to function as a tumor suppressor gene 
by inducing apoptosis of various cancer cells and inhibiting cell proliferation. 
Transcript levels of these two genes were measured in nevi, primary, and 
metastatic melanoma tissue samples using quantitative RT-PCR and compared 
using methods in statistical analysis. While neither gene showed a statistically  
significant difference in expression among the three types of tissues, the 
observation that IL-6 is essentially absent in nevi tissue and up-regulated in 
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primary and metastatic tissue points to more evidence linking a host immune 
response to tumorigenesis. This favors more investigation into this gene as well 
as other inflammatory genes to continue the development of novel biomarkers 
that will help to predict melanoma progression and response to therapeutics.  
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INTRODUCTION 
The skin is the largest organ of the human body. It is comprised of three 
layers listed here from superficial to deep: epidermis, dermis, and hypo-dermis. 
Skin cancer is an umbrella term for the uncontrolled growth of abnormal cells 
originating from the skin. Specific cancers are termed for the type of skin cell 
from which the aberrant growth originates. For example, basal cell carcinoma 
originates from the basal cells of the epidermis. Squamous cell carcinoma 
originates from squamous cells in the epidermis. Finally, melanoma, the focus of 
this paper, is generated from the uncontrolled growth of melanocytes located in 
the basal layer of the epidermis.  
Although melanoma comprises only four percent of all skin cancers, it is 
the most aggressive subset of skin cancer (Moretti 1) which leads to the greatest 
number of skin cancer-related deaths (Maio 10). The American Cancer Society 
estimated that in 2010 there were 68,000 new cases of melanoma and over 
8,000 melanoma-related deaths (Menaa 1).  As the “sixth most common cancer 
(Dar 2071)” in the United States, melanoma arises from a type of cell called a 
melanocyte, which is found in the bottom layer of the epidermis. Melanocytes 
produce the substance melanin, which is responsible for skin color and for 
protecting the deep layers of the skin from exposure to ultraviolet radiation. 
Melanoma incidence is rising at a rate faster than other cancer, with particular 
increases being seen primarily in young Caucasian women (Maio 10). Risk 
factors for developing this cancer include prolonged or repetitive exposure to 
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sunlight, a family history of melanoma, and several nevi, or birthmarks (Manaa 
1). Currently, the most effective curative treatment for melanoma is early stage 
surgical intervention, such as excision of the cutaneous lesion.  
Skin lesions that may present as melanoma are compared to the ABCDE 
system (Table 1) to discern whether suspicious spots deserve further attention. 
Asymmetry is defined as one half of the lesion appearing different than the other 
half. Border irregularity or a poorly defined border is another phenotypic 
characteristic to look for. Color variation is simply a difference in color in one area 
of the lesion compared to another. A diameter of greater than 6mm is also 
another consideration to take into account. Finally, an evolving lesion is one that 
looks different than surrounding moles or birthmarks, or the lesion has been 
changing in size, shape, or color (Shenenberger 162). 
Table 1: ABCDE System of Assessing Potential Melanoma Lesions 
This is a simple aid for melanoma awareness and early recognition of 
cutaneous lesions (Shenenberger 162).   
ABCDE System 
A Asymmetry 
B Border Irregularity 
C Color Variation 
D Diameter ≥ 6mm 
E Evolution 
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Biopsies of any suspicious lesions provide the most accurate clinical 
diagnoses and determine the most appropriate treatments (Testori 22). 
Histological and clinical analysis of the sample is essential for proper staging of 
the growth, which ultimately determines the prognosis of the patient’s disease. 
Staging of melanoma tumors is determined by analysis of thousands of patients 
in the American Joint Committee on Cancer (AJCC) Melanoma Staging 
Database. This system is continuously changing as more information about 
melanoma surfaces. The most recent revisions to the AJCC’s staging system 
appeared in 2009 and represent the AJCC’s seventh edition of the recommended 
guidelines for melanoma staging (Tables 2a, 2b, 2c, 3). Essential characteristics 
of tumors that the staging system takes into account are tumor thickness, mitotic 
rate, and ulceration. Mitotic rate is defined as the number of cells dividing per 
millimeter squared. In the newest edition of the melanoma staging system, more 
emphasis has been put on mitotic rate in primary tumors. The AJCC also 
incorporated increased serum lactate dehydrogenase (LDH) levels as a 
significant prognostic predictor for patients with stage IV melanoma.  
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Table 2a: AJCC Melanoma Staging Seventh Edition: Primary Tumor (T): 
This chart defines staging of primary tumors taking into account tumor thickness 
and presence or absence of ulceration and/or mitoses (Dummer 87). 
Classification Thickness (mm) Ulceration Status/Mitoses 
T in situ Not Applicable Not applicable 
T1 ≤ 1.00 a: without ulceration and 
mitosis < 1/mm2 
b: with ulceration or 
mitosis ≥ 1/mm2  
T2 1.01 – 2.00 a. without ulceration 
b. with ulceration 
T3 2.01 – 4.00 a. without ulceration 
b. with ulceration 
T4 > 4.00 a. without ulceration 
b. with ulceration 
 
Table 2b: AJCC Melanoma Staging Seventh Edition: Tumors with Lymph 
Node Involvement: This defines staging of tumors that involve regional lymph 
nodes taking into account the number of nodes it has reached as well as degree 
of lymph node involvement (Dummer 87). 
Classification Number of Metastatic 
Nodes 
Nodal Metastatic Burden 
N0 0 Not Applicable 
N1 1 a: micrometastasis 
b. macrometastasis 
N2 2 - 3 a: micrometastasis 
b. macrometastasis 
c. in transit 
metastasis/satellites 
without metastatic nodes 
N3 4+ metastatic nodes, or 
matted nodes, or in 
transit 
metastases/satellites 
with metastatic nodes 
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Table 2c: AJCC Melanoma Staging Seventh Edition: Metastatic Tumors: 
This section defines staging of tumors that have metastasized, or spread, to 
other areas of the body. It takes into account the site to which the tumor has 
spread and the patient’s serum LDH levels (Dummer 87). 
Classification Site Serum LDH Levels 
M0 No distant metastases Not Applicable 
M1a Distant skin, 
subcutaneous, or nodal 
metastases 
Normal 
M1b Lung metastasis Normal 
M1c All other visceral 
metastases 
Normal 
 Any distant metastasis Elevated 
 
Table 3: AJCC 2009 Clinical Staging of Melanoma: Staging of primary 
melanocytic lesions based on lymph node involvement and degree of metastasis 
(Balch 6201).  
Stage T N M 
0 In situ N0 M0 
IA T1a N0 M0 
IB T1b 
T2a 
N0 M0 
IIA T2b 
T3a 
N0 M0 
IIB T3b 
T4a 
N0 M0 
IIC T4b N0 M0 
III Any T N> N0 M0 
IV Any T Any N M1 
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Due to continual advances in cancer and melanoma research, this staging 
system will change in the future, most likely to include more serum or tissue 
biomarkers. Currently, prognosis for melanoma patients is based on the histology 
of the primary tumor and the extent of metastases if any. Thus, assessment of 
patients is either invasive or requires imaging using radiographic or nuclear 
medicine. While techniques such as computed tomography (CT) scanning, 
PET/CT scanning, and MRI are helpful in obtaining images of lesions in patients 
with advanced stage melanoma, they are of practically no use at the time of initial 
diagnosis and would even be considered excessive. Detection rate of imaging is 
low for early stage patients with a false-positive rate of 10-20% (Mohr 18). 
Moreover, they are a financial burden on patients as they are expensive and not 
widely available.  
Regrettably, the prognosis for metastatic melanoma is extremely poor 
(Maio 10). For those afflicted with metastatic melanoma, the average overall 
survival time is between 8 and 18 months (Menaa 1). Up until September 2011, 
treatment for melanoma was limited to chemotherapy with dacarbazine and high 
dose interleukin-2 (IL-2), a cytokine that induces T lymphocyte activation and 
proliferation. Both of these treatments demonstrated extremely poor response 
rates of less than 15%. Since 2011, the Food and Drug Administration (FDA) has 
approved a few treatments for advanced stage melanoma. One example is the 
drug vemurafenib, an inhibitor of mutant BRAF V600E. This BRAF mutation is the 
most common genetic mutation seen in human melanoma (Das Thakur 251), 
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making it a valuable target of interest. The BRAF gene encodes a 
serine/threonine protein kinase that plays a role as a downstream effector in the 
Ras/Raf/MAP kinase cellular signaling pathway which controls cell division and 
differentiation. The BRAF V600E mutation is caused by the substitution of the 
amino acid valine (V) by the amino acid glutamate (E) at the 600th codon (Tan 
259) and results in an excessive growth signal that causes a cell to continuously 
divide and proliferate. Vemurafenib treatment is advantageous because it is 
selective for this particular BRAF mutation. Therefore, BRAF proteins that are 
normally functioning, otherwise known as wild-type, are spared. Clinical trials 
utilizing this drug demonstrated significant tumor regression as well as higher 
response rates relative to those after chemotherapy treatment (Menaa 2). 
Drawbacks of this drug, however, include a short median duration of response 
(MDR) of approximately six months, no benefits to those patients who do not 
harbor the particular BRAF V600E mutation, toxic side effects, and the 
susceptibility of acquiring resistance to the drug (Das Thakur 251).  
Pegylated interferon alpha-2 (PEG-IFN) is another drug recently approved 
by the FDA for the treatment of post-surgical resection stage III melanoma 
patients. In clinical trials, using PEG-IFN as an adjuvant therapeutic to the drug 
temozolomide demonstrated a response rate of 31% and an average overall 
survival of one year. While currently benefits of PEG-IFN are limited, as this 
treatment is not as successful as chemotherapy, further research and studies 
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suggest that this therapy holds significant clinical benefits for those patients 
presenting with advanced stage melanoma (Agarwala 1449). 
Understanding the biological and physiological pathways underlying the 
progression of melanoma is essential for developing effective and inexpensive 
therapeutic agents that effectively treat the disease. Presently, there are no 
available tests to predict if early stage tumors will progress to metastasis. 
Molecular signatures of melanoma progression, however, can be used to 
develop accurate prognostic markers and effective targeted treatments (Ryu 1). 
Biomarkers for melanoma, for example, exploit the genetic mechanisms of 
melanoma’s invasiveness and, if identified, can lead to the generation of 
relatively inexpensive treatments. Biomarkers are genetic fingerprints that can 
serve as powerful diagnostic and prognostic tools for melanoma. They are 
generally factors that are specific to the tumor or specific to the host, and 
correlate with the tumor’s biological behavior and, thus, the patient’s prognosis 
(Gogas 8). Biomarkers can be used to evaluate the risk or presence of disease 
and can also predict the effect of an intervention or therapy (Gogas 8).The most 
reliable prognostic determinant presently is the stage of the disease. Patients 
with stage I melanoma have a 95% survival rate while patients with stage IV 
melanoma have a 7% survival rate. Moreover, patients within each category 
behave differently and so it is important to discern which patients have a more 
aggressive form of melanoma and which patients have a relatively mild form of 
the disease (Maio 13).  Reliable prognostic biomarkers have advantages such as 
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accurate diagnosis, appropriate prioritization of treatment and determination of 
patient populations that will benefit most from each types of therapy (Maio 13). 
They also provides for monitoring of treatment and response. Many candidates 
for potential cutaneous melanoma biomarkers have been identified (Table 4) but 
require further testing and validation.  
 One example of a potential cutaneous biomarker is the repetitive genomic 
sequence, (LINE-1). A characteristic genetic event in cancer development is the 
hypo-methylation of repetitive elements, such as LINE-1. A recent study of cells 
from patients with stage III melanoma showed that those patients with hypo-
methylated LINE-1 sequences have a significantly better prognosis compared to 
patients with hyper-methylated LINE-1 sequences (Maio 13). Thus, evaluating 
the degree of methylation of this particular gene sequence can prove to be an 
important tool for predicting the clinical course of human melanoma and 
prioritizing treatment accordingly for melanoma patients (Maio 13). 
 Testing patient serum for biomarkers is also a relatively inexpensive 
method of determining disease progression. LDH and S100B have both been 
widely accepted as prognostic blood serum markers. LDH is an enzyme that 
catalyzes the conversion of lactic acid to pyruvate, a key substrate for many of 
the body’s metabolic pathways. LDH is found in significantly increased 
concentrations in patients with stage IV melanoma and was found to be the first 
indication of metastases in 12% of patients (Mohr 18). However, more research 
needs to go into the exact role of LDH concentration in metastatic melanoma 
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patients as an increase in LDH can be caused by many other factors such as 
exercise, liver disease, and hemolysis. Nonetheless, the overwhelming data that 
suggests stage IV melanoma patients with increased serum LDH levels have 
shorter survival rates earned serum LDH levels as a consideration for the newest 
melanoma staging system. 
 S100B is a protein that is normally localized to the cytoplasm or nucleus of 
cells. It, along with many other S100 proteins, functions to regulate cellular 
processes such as cell cycle progression and differentiation. The S100B protein 
is found in primary melanoma tumors and has proven to positively correlate with 
tumor invasiveness, cell proliferation, and the extent of metastasis. S100B 
measurements, however, have low sensitivity in patients with early stage 
melanoma and, thus, cannot prove to be a reliable marker until stage III and IV of 
the disease when it is at higher serum levels (Wevers). Both serum markers, 
however, seem to be preferable alternatives to expensive radiologic imaging and 
thus prove to be extremely valuable laboratory investigations to the melanoma 
community  
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Table 4. Potential Cutaneous Melanoma Biomarkers: Potential cutaneous 
melanoma biomarkers detected by IHC analysis of tissue microarrays. These candidates 
still need confirmation from independent data sets or data sets collected from clinical 
trials (Gogas 10).  
 
Biomarker Observation 
Hsp90 Increased expression in melanomas compared with nevi 
and in metastatic compared with primary tumors. 
Correlation with tumor thickness and higher Clark level. No 
association seen between high expression and survival in 
the subsets of patients with primary or metastatic tumors. 
RGS1 Correlation with increased tumor thickness, mitotic rate and 
vascular involvement; reduced RFS and DSS. 
Osteopontin Correlation with increased tumor thickness, higher Clark 
level, mitotic index; reduced RFS and DSS; predictive of 
SLN metastasis and SLN burden. 
HER3 Correlation with increased cell proliferation, tumor 
progression; reduced survival. 
ING4 Reduced levels associated with melanoma thickness, 
ulceration and poor DSS and OS. 
ING3 Reduced nuclear expression associated with poor DSS; an 
independent prognostic factor to predict patient outcome. 
NCOA3 Increased levels predictive of SLN metastasis and 
associated with poor RFS and DSS. 
MCM4 Increased levels associated with poor DFS and OS. 
MCM6 Increased levels associated with poor DFS and OS. 
 
 
 
Melanoma and Immuno-Oncology 
 Cancer cells secrete various cytokines, chemokines, and growth factors. 
These substances influence cancer’s aggressiveness, such cell proliferation, 
invasion, and survival, as well as the sensitivity of the tissue surrounding the 
tumor (Moretti 6). Melanoma is said to be a “model tumor for immuno-oncology 
(Maio 10)” as “melanoma tumor-associated antigens were among the first cancer 
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antigens to be identified and classified (Maio 10)”. Further studies showed that 
these antigens were also present in other tumors. Tumor-associated antigens are 
recognized by the host’s own antibodies and T-cells. This interaction promotes 
an immune response directed toward the tumor. Examples of tumor-associated 
antigens in melanoma include tyrosinase and Melan-A, which are expressed by 
normal and malignant cells derived from melanocytes only, and NY-ESO-1, 
which is expressed in various types of tumors (Maio 12). Much research has 
gone into investigating the immune response to cancer using melanoma as a 
model due to the relative ease of access to melanoma lesions. Melanoma is also 
“one of the easiest cancers to adapt to tissue culture, meaning tissue samples 
and cell lines are readily available for research (Maio 10).” 
 More evidence pointing to an immune response to melanoma includes the 
spontaneous regression of “13.8-50% of primary melanomas (Maio 12).” This is 
defined as the “partial or complete disappearance of a malignant tumor in the 
absence of treatment (Maio 12).” This may be the result of an immune response 
against the tumor cells as histological analysis of a regressing lesion shows 
infiltration of cytotoxic T lymphocytes, or CD8+ T cells (Maio 12). As the 
melanoma progresses, however, melanoma cells may evolve to avoid the 
immune system, which explains why spontaneous regression is not seen in 
metastatic melanoma.  
 Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) 
utilizes anti-tumor lymphocytes that have been identified, generated and grown 
13 
 
 
 
outside of the patient’s body and then administered to the cancer patient via 
infusion. This treatment has shown to result in the complete regression of 
metastatic melanoma in patients that are resistant to the current melanoma 
treatments. However, due to the cost and effort of producing TIL cultures for 
individual patients, adoptive cell therapy use is limited (Maio 13).  
 Another observed method of immunotherapy is the use of antibodies to 
target T lymphocytes. Ipilimumab, another drug recently approved by the FDA in 
the last two years, is an antibody targeted against cytotoxic T-lymphocyte-
associated antigen-4 (CTLA-4) resulting in increased T-cell activation and 
proliferation to produce an enhanced immune response against tumors. Phase 
three clinical trials have shown that administration of ipilimumab in pre-treated 
patients has improved overall survival (Maio 13). In 2011, ipilimumab became an 
approved treatment for metastatic melanoma in the United States, the first 
treatment since IL-2 was approved in 1998 (Maio 13). When used in conjunction 
with darcabazine chemotherapy, the response rate increased 5% and the overall 
survival increased by approximately four months (Menaa 2). However, since 
ipilimumab is an immuno-therapeutic, it can lead to adverse immune-related 
systemic effects such as hepatitis or dermatitis. Nonetheless, when used 
singularly, ipilimumab boasts a higher MDR and overall survival duration than 
those observed with vemurafenib, demonstrating a need to combine treatment 
drugs in efforts to provide complementary therapeutic benefits.  
14 
 
 
 
 With all of the promises of these current immuno-therapies, it is important 
to note that these treatments hold extremely toxic side effects. Most tumor-
associated antigens are also expressed by some normal tissues. Treatments 
against these antigens can result in an immune response against the body’s own 
antigens, resulting in destruction of normal tissue (Maio 13). This underscores 
the need to identify and develop biomarkers to help discern which patients would 
be most likely to respond to treatment, since currently the best predictor of 
survival for patients with melanoma is the stage of the cancer. 
  
 Interleukins 
 Interleukin-6 is normally a cytokine secreted by T-cells and macrophages 
to stimulate the immune response following infection or trauma. In tumor 
progression, IL-6 activates connective tissue and inflammatory cells but does not 
have a role in tumor invasiveness. A previous study done by S. Moretti et al 
evaluated the effects of catecholamine stimulation on cancer cell movement. The 
group found that stimulating a melanoma microenvironment with epinephrine and 
norepinephrine results in an increase in production of IL-6, along with IL-8 and 
vascular endothelial growth factor (VEGF). These researchers also observed that 
IL-6 activates dermal fibroblasts, which generate connective tissue and collagen 
in the skin to allow the skin to recover from injury. Interestingly, these dermal 
fibroblasts express the protein alpha-smooth muscle actin (α-SMA) indicating that 
these dermal fibroblasts are moving towards a myofibroblastic phenotype. 
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Myofibroblasts are cells that are in between fibroblasts and smooth muscle cells. 
They have contractile properties as well as the ability to produce collagen and 
connective tissue. It is known that stromal fibroblasts within tissues transition to 
myofibroblasts, giving them more contractile properties which allow them to 
cross-talk with tumor cells to increase aggressiveness. Activated fibroblasts also 
secrete cytokines such as VEFG which induce angiogenesis, or the production of 
new blood vessels to nourish a growing tumor. Norepinephrine and Epinephrine 
are agonists of a receptor known as the β-adrenergic receptor, which is 
expressed in human melanocytic lesions. Recent studies show that antagonists 
of this receptor may reduce melanoma progression and thus may serve as new 
therapeutic agents for the disease. 
 
Insulin-Like Growth Factor Binding Proteins 
 This super family of proteins contains six high affinity binders, IGFBP 1- 6. 
IGFBP-3 in particular is found in the serum in the highest quantities compared to 
the other binding proteins. This group of proteins functions to regulate the 
availability of insulin to its target tissues. IGFBP3 is of interest here because, 
along with its functions in the circulation as well as the extra- and intra-cellular 
environments, IGFBP-3 inhibits cell proliferation and induces apoptosis of various 
cancer cells, including cells of prostate, breast, and lung cancer (Gombos 2435). 
IGFBP3 suppresses cell growth by way of a couple pathways. In the IGF 
receptor-dependent pathway (Figure 1), IGFBP3 binds to IGF-1 and -2 
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X 
preventing these ligands from binding to and activating the IGF-1 receptor, 
effectively suppressing the cell growth signal altogether (Dar 2071).  
 
      
                      
        (Extracellular) 
 
     -------------------------------- IGF-1R----------------------------------------------------- 
 
 
        (Intracellular) 
             Ras Pathway               AKT Pathway    
 
 
 
Cell growth and Proliferation           Inhibition of Apoptosis 
 
 
Figure 1: IGF-1R Mediated Cell Signaling: The ligands IGF-1 and IGF-2 
normally bind to the IGF-1 receptor, which is a trans-membrane tyrosine kinase 
receptor. Ligand binding causes phosphorylation of mediator proteins that 
activate various signaling pathways leading to cell growth, proliferation, and 
inhibition of apoptosis (Gombos 2435). IGFBP3 binds to IGF-1 and IGF-2 and 
suppresses this process (Dar 2071).  
 
IGF-1, IGF-2 IGFBP3 
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In the IGF receptor-independent pathways IGFBP3 itself interacts with 
various signals that suppress cellular growth and proliferation. In a prostate 
cancer study done in 2011, IGFBP-3 was established as a “metastasis 
suppression gene” and was acknowledged to inhibit proliferation and induce 
programmed cell death of different cell types. Although these mechanisms are 
not well understood, it is suggested that IGFBP-3 increases the ratio of pro-
apoptotic proteins, such as Bax and Bad, to anti-apoptotic proteins, such as Bcl-2 
and Bcl-XL. IGFBP-3 may also interact with death receptors such TNF-α to 
activate the caspases involved in the death receptor-mediated pathway of 
apoptosis (Figure 2).  
 
Figure 2: Summary of Extrinsic and Intrinsic Pathways of Apoptosis: This 
schematic summarizes both pathways in which programmed cell death occurs. A 
brief detailed description is in the text.  
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 In the extrinsic pathway of apoptosis, ligand binding to death receptors 
cause activation of Caspase-8 and -10. These caspases then cleave pro-
caspase-3/-6/-7 into activated Caspase-3/-6/-7 which activate downstream 
targets and set off the apoptotic process. IGFBP3 is speculated to produce a 
stimulatory effect on these death receptors. In the intrinsic pathway, also known 
as the mitochondrial pathway, death stimuli target mitochondria either directly or 
through transduction by pro-apoptotic factors. Mitochondria release apoptogenic 
factors which cleaves pro-caspase-9 into caspase-9, which in turn activates 
effector caspases. IGFBP3 is believed to produce a stimulatory effect for the 
production of these pro-apoptotic factors (Ramalho 55). 
Aside from apoptosis, there are studies that suggest IGFBP-3 plays a role 
in controlling cell cycle progression. Breast cancer researchers found that the 
protein induced G1 cell cycle arrest in certain breast cancer cells. Although the 
exact mechanisms are unknown, researchers speculate it might be due to 
decreased expression of cyclins, which are cell cycle regulatory proteins (Wu 
127).  
In a study exploring IGFBP3 expression in melanoma, researchers found 
that IGFBP3 mRNA and protein levels are significantly down-regulated in various 
melanoma cell lines relative to normal melanocyte cell lines. Further investigation 
found that the silencing of IGFBP3 in melanoma is due to excessive methylation 
of the DNA at the promoter region for the IGFBP3 gene (Dar 2073). This DNA 
19 
 
 
 
hyper-methylation hinders effectively hinders transcription of the target gene 
(Figure 4).  
 
Current Study 
 The aims of this study were to determine if these genes could serve as 
biomarkers for melanoma based on their differential RNA expression levels found 
in the progression of the cancer. Achievement of these goals would not only 
provide for earlier detection and treatment of the cancer but also improved 
prognosis for those already affected. The experimental PCRs that were run in 
this study were designed to amplify two targets in a single reaction, also known 
as duplexing. These two targets were the gene of interest (IL-6 or IGFBP-3) as 
well as luciferase, an exogenously added internal control. Duplexing required 
extensive optimization of reaction conditions to create an environment where 
both genes could achieve excellent amplification while avoiding antagonistic 
effects on each other while in the same tube. Reaction conditions that needed to 
be taken into account included primer annealing temperature and the 
concentrations of each gene’s primers and probes in the reaction mixture.  
 In our attempts to link IL-6 gene expression to melanoma progression, we 
hypothesized that there would be a direct correlation between IL-6 gene 
transcript levels, and melanoma progressiveness as supported by the discussion 
regarding a possible contribution of the immune system to cancer 
aggressiveness. In terms of IGFBP3, many studies point to the role this protein 
has as a possible tumor suppressor protein. The researchers who investigated 
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the role of IGFBP3 in melanoma established that this protein is essentially 
silenced in melanoma cell lines. As we attempted to quantify IGFBP3 transcript 
levels in melanoma cell lines that vary in melanoma progressiveness, we 
hypothesized that there would be an inverse correlation between IGFBP3 
expression and melanoma development as supported by the discussion 
concerning this protein’s role in hindering cell growth and proliferation as well as 
in enhancing cellular apoptosis.   
 
Methods and Materials 
 Twenty-seven human melanocytic lesions were evaluated for gene 
expression levels. The series included nine nevi samples, nine primary 
melanoma samples, and nine metastatic melanoma samples. Nevi, or a nevus, 
are defined as the result of “intense melanocytic activity around the dermo-
epidermal junction (Rook 185).” Essentially these are many melanocytes that 
proliferate into the dermal layer of the skin. Consequently, there is a lot of 
pigment present giving rise to what the lay person recognizes as birthmarks or 
moles. Nevi are benign if they are symmetrical and circumscribed lesions, 
indicating a controlled proliferation of the melanocytes. Primary melanoma 
indicates abnormal proliferation of melanocytes that invades the deeper layers of 
the skin in a vertical growth pattern. Metastatic melanoma occurs when the 
abnormally dividing melanocytes enter the blood stream and get taken up into 
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tissues of other organs separate from the original site. In metastatic melanoma, 
tumors begin to appear on different organs as well as in lymphatic tissue.  
 These patient samples were randomly selected and provided by the 
Department of Dermatology at Boston University School of Medicine in Boston, 
Massachusetts. Previous researchers in the lab received these samples as 
formalin-fixed, paraffin-embedded tissues, adhered to microscope glass slides. 
These researchers processed the tissue samples with Arcturus Paradise PLUS 
Whole Transcript Reverse Transcription Reagent System supplied from Applied 
Biosystems by Life Technology. RNA extraction and isolation from the tissue 
slides were performed according to manufacturer’s instructions. The samples 
underwent a series of washes in xylene for a total of fifteen minutes to remove 
the paraffin. The tissues were then scraped off of each slide using sterile scalpels 
and incubated with Proteinase K for 16 to 20 hours. After incubation, 10 nano-
grams of luciferase RNA were added to each sample as an internal control for 
RNA extraction and isolation. The RNA from each sample was isolated using a 
conditioned purification column as well as a binding buffer and ethanol. The 
samples were washed several times and ultimately an elution buffer was used to 
isolate about 11 µL of RNA. The isolated RNA also underwent a DNase 
treatment according to the manufacturer’s instructions to ensure each sample 
was free of contaminating DNA. 
 These previous researchers also reversed transcribed the isolated RNA to 
cDNA using SuperScript III First-Strand Synthesis System for RT-PCR supplied 
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by Invitrogen. Reverse transcription was carried out according to manufacturer’s 
instructions. The isolated RNA was primed with random hexamers and combined 
with a 10 µM dNTP mix. The RNA and the mixture was denatured at 65°C for five 
minutes and then held at 4°C for one minute. A mixture of 10X RT Buffer, 25 µM 
MgCl2, 0.1M DTT, RNaseOUT, and SuperScript III RT was added to the samples 
and the entire solution was heated to 25°C for 10 minutes, 50°C for 50 minutes, 
and then cooled to 8°C for 5 minutes. RNase H was added and the samples 
were heated to 37°C for 20 minutes. The entire procedure yielded approximately 
60 µL of cDNA for each tissue sample. 
 Primers and probes for duplex quantitative real-time PCR were designed 
for IL-6 and IGFBP3 using the Primer BLAST program provided by the National 
Center for Biotechnology Information website. Long primers were designed to 
give a 500 base pair cut of our gene of interest. Short primers were designed to 
generate a 50 base pair cut of our gene of interest within the 500 base pair 
segment. The 500 base pair segment was amplified to produce DNA of just that 
segment that would be used as template DNA from which a standard curve of the 
gene would be generated. The mRNA sequences for the respective genes were 
specified by their given accession number. The primer and TaqMan probe 
sequences were as follows: 
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Table 5. Primer and Probe Sequences: Forward and reverse nucleotide 
sequences for primers used to amplify cDNA of gene sequences using qRT-PCR  
 
IL-6 (Short Primers) 
Forward: 5’-GCTGCAGGCACAGAACCA-3’ 
Reverse: 5’-GCTGCGCAGAATGAGATGAG-3’ 
           
IL-6 (Long Primers)  
Forward: 5’-ACAGCCACTCACCTCTTCAG-3’                                                                         
Reverse: 5’-CATTTGCCGAAGAGCCCTCA-3’ 
 
IL-6 (TaqMan MGB Probe) 
5’-6FAMTGGCTGCAGGACATGAMGBNFQ-3’ 
 
IGFBP3 (Short Primers) 
Forward: 5’-CAAGCGGGAGACAGAATATGG-3’ 
Reverse: 5’-CAGGTGATTCAGTGTGTCTTCCA-3’ 
 
IGFBP3 (Long Primers)                                                                           
Forward: 5’-CTTCCTGCCTGGATTCCACAG-3’ 
Reverse: 5’-CTAGCATTTCCTGGAGCTGGC-3’ 
 
IGFBP3 (TaqMan MGB Probe) 
5’-6FAMCCCTGCCGTAGAGAAMGBNFQ-3’ 
 
 
 
 According to previous studies, the genes were shown to be highly 
expressed in the Mel 11 human melanoma cell line. RNA from Mel 11 cells was 
extracted using the RNeasy Mini Kit Part 1 from Qiagen. Protocol was followed 
as recommended by the manufacturer. After the RNA from the Mel 11 cells was 
extracted and isolated, its concentration was measured using the NanoDrop 
2000 Spectrophotometer from Thermo Scientific. This RNA was then reverse 
transcribed into Mel 11 cDNA, which would be used as the template genetic 
sequence for the generation of the target gene amplicon. The reverse 
transcription process was completed using the High Capacity RNA-to-cDNA Kit 
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supplied by Applied Biosystems. Reverse transcription was carried out according 
to manufacturer’s instructions. 1µg of RNA was used for every 20µL reaction. 
10µL of 2X RT Buffer, 1µL of 20X Enzyme Mix, and nuclease-free water, quantity 
sufficient to 20µL, were combined into one reaction tube. Another reaction tube 
was prepared with all components except for the 20X Enzyme Mix to serve as 
our RT negative control. The reaction tubes were incubated at 37°C for 60 
minutes, heated to 95°C for 5 minutes, and then held at 4°C for 60 minutes.  
 Prior to running the multiplex PCR experiments, the assays for each 
individual target were optimized. To determine the efficiency of each reaction, a 
standard curve was generated for each target gene. PCR amplifications of the 
target gene of interest to generate the standard curve were done using Sybr 
Green reagents. The reaction volume of 20µL contained 10µL of iQ Sybr Green 
Supermix (Bio-Rad), 1µL of Mel 11 cDNA to be used as the template, 0.5µL of 
the forward long target gene primer, 0.5µL of the reverse long target gene primer, 
and 8µL of distilled, DNase-free, RNase-free water. PCRs were run on 96-well 
plates and all were done as standard two hour runs. The run method consisted of 
the following steps: a ten minute holding stage at 95°C; a cycling stage 
consisting of 45 cycles where one cycle consisted of thirty seconds at 95°C, thirty 
seconds at 60°C, and thirty seconds at 72°C; a melting curve stage consisting of 
holding the reaction at 95°C for fifteen seconds, 60°C for one minute, and finally 
95°C for 15 seconds. The melting curves ensured that the correct fragment was 
amplified. To check efficiency and quality of the reaction, actin was amplified as a 
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positive control. Actin is a gene that is found in virtually all cells and thus it serves 
as an ideal control for determining whether or not a reaction was successful. A 
water control was also used to check for contamination of any of the reagents. 
The amplified DNA product was separated via gel electrophoresis using 1.5% 
agarose gel. The gel was run for approximately two hours at 120 volts. The gel 
was visualized using a ultra-violet trans-illuminator and pictures of the gel were 
taken using the Gel Logic 100 Imaging System by Kodak. The DNA fragment 
bands at the 500 base pair mark were excised from the gel and extracted and 
purified using the QIAquick Gel Extraction Kit from Qiagen. Protocol for this step 
was followed as recommended by the manufacturer. After the DNA was isolated, 
its concentration was determined using the NanoDrop.  
 Each gene’s respective DNA was serially diluted in ten-fold dilutions from 
concentrations ranging from 1 nano-molar (10- 9) to 1 femto-molar (10-15). These 
dilutions were used as template DNA with their respective short primers and 
TaqMan probes. Each reaction consisted of 10µL of TaqMan Universal Master 
Mix, 1µL of DNA, 0.3µL of target gene short forward primer, 0.3µL of target gene 
short reverse primer, 0.25µL of target gene probe, and 8.15µL of nuclease-free 
water to produce a 20µL reaction volume for each reaction. The thermal cycling 
conditions for RT-PCR analysis to produce the standard curves were as follows: 
denaturing at 95°C for 5 minutes, 60 cycles of primer annealing and elongation at 
95 °C  for 30 seconds and 55°C for 1 minute each cycle, and a final holding 
stage at 62°C for 5 minutes. Each sample was run in duplicates. 
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 The mass of one gene copy (m) for each gene was calculated using the 
formula: m = [n] [1.096e-21 g/bp] where n is the number of base pairs in the each 
gene’s DNA segment (~500). The ratio of concentration to m produced the 
number of gene copies in each dilution. The Ct value for each reaction was 
plotted against the log of their respective copy numbers to produce a standard 
curve of each gene (Figures 3, 4, 5). Each standard curve has its own linear 
regression equation which would be used to calculate gene copy numbers in the 
experimental runs. Each regression equation also has an R2, or a coefficient of 
determination, value which is an indicator of how well the regression line fits the 
data. An R2 value closer to 1.0 demonstrates that the trend line fits the data well 
and, thus the curve will prove as a reliable measure. Moreover, the fact that there 
was detectible amplification of genes at a dilution as high as 1femto-molar 
indicates that the reaction conditions have a high degree of sensitivity and 
specificity, proving that they are optimal for experimentation. 
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Figure 3. Melan A Standard Curve: Standard curve of Melan A gene relating Ct 
values of reactions at different dilution to the log of gene copy numbers contained in 
each dilution. The data above was provided by a previous researcher of the Alani Lab.  
 
 
 
Figure 4. IL-6 Standard Curve: Standard curve of IL-6 gene relating Ct values of 
reactions at different dilution to the log of gene copy numbers contained in each dilution.  
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Figure 5. IGFBP-3 Standard Curve: Standard curve of IGFBP3 gene relating Ct 
values of reactions at different dilution to the log of gene copy numbers contained in 
each dilution. 
 
Using the reaction conditions that were optimized during the standard curve 
experiments, RT-PCR experiments were run to amplify IL-6 and IGFBP-3 in all 
twenty-seven tissue cDNA samples. To minimize bias, only one of the two genes 
of interest was amplified per run. Since each cDNA sample was exogenously 
spiked with the reference gene luciferase to serve as an internal control, 
luciferase was amplified in each run as well. This allowed for normalization of 
gene transcript levels from sample to sample since the luciferase expression 
level would be constant across all samples and would not be affected by the 
experimentation. Normalization needs to occur during quantification of results 
from RT-PCR experiments to ensure the data is biologically meaningful. It is 
simply standardizing the obtained target quantity to make sure target quantities 
from equal amounts of sample are compared. Each reaction was run in replicates 
of two. Since there were two targets in a single reaction, two different fluorescent 
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dyes were used for the detection and quantization of gene transcript levels. The 
ratio of target gene and luciferase was calculated to normalize transcript levels of 
each gene. The tissue levels of each target gene transcript were determined from 
the standard curves.  
Further normalization of the target gene copy numbers was performed to 
provide more reliable results. Melan-A is found in all melanocytes and thus was 
used as a reference gene to correct for the size of the melanocytic lesion since 
metastatic tissue samples are generally larger than primary and nevi. Data 
regarding Melan-A was provided by a previous researcher. The level of gene 
expression in the tissue samples are presented as a ratio of target gene copy 
numbers and Melan-A copy numbers.  
 
Results: 
 IL-6 behaved according to our hypothesis in that gene transcript levels 
increased in primary and metastatic melanoma samples relative to those in the 
nevi samples (Figure 6). In fact, IL-6 was essentially absent from the nevi 
samples, indicating that these benign lesions most likely do not express the 
interleukin. Increased gene expression in the aggressive melanoma samples 
indicates the presence of a host immune response to the growing tumor.  
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Figure 6. IL-6 vs. Melan A: This graph depicts the copy number ratio between IL-6 
and Melan-A to standardize the size of the melanoma lesions. IL-6 is nearly absent in all 
of the nevi samples and starts to become up-regulated in primary and metastatic 
melanoma samples. 
 
Statistical analysis was performed comparing IL-6 levels in nevi versus 
primary, primary versus metastatic, and nevi versus metastatic samples. 
Differences were evaluated using a two-tailed hypothesis test assuming equal 
variances among nevi and primary melanoma, primary and metastatic 
melanoma, and nevi and metastatic melanoma. Differences were considered 
significant at p ≤ 0.05 (Figure 7). 
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Figure 7. IL-6 Box and Whisker Plot: Box and Whisker plot comparing copy 
number ratios among the three types of tissues tested for IL-6 gene expression. 
Statistical analysis is discussed in the text. Respective p-values are noted. Note that 
sample size (n) for each tissue type was n = 9. The top of each green bar indicates the 
value of a maximum outlier.  
 
  
Although we saw a predictable trend in IL-6 expression levels, neither tissue 
type showed a statistically significant difference in expression when compared 
against each other. On the other hand, IGFBP3 expression levels were the 
opposite of what we hypothesized (Figure 8). Rather than decreasing in 
expression with increased melanoma aggression, some primary and metastatic 
tissues expressed more IGFBP3 transcript levels than those in the nevi samples. 
Based on our data, however, it is difficult to discern a conclusive trend regarding 
IGFBP3 expression in our melanoma samples.  
p=0.159 
p=0.141 
p=0.465 
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Figure 8. IGFBP-3 vs. Melan-A: This graph depicts the copy number ratio between 
IGFBP-3 and Melan A to account for differences in size of the melanoma lesions. Here 
we do not see a consistent trend of differences in transcript levels among the different 
types of tissue. Contrary to our hypothesis, IGFBP3 levels seem to increase in primary 
and metastatic tissue samples.  
 
Statistical analysis was performed comparing IGFBP3 levels in nevi 
versus primary, primary versus metastatic, and nevi versus metastatic samples. 
Differences were evaluated using a two-tailed hypothesis test assuming equal 
variances among nevi and primary melanoma, primary and metastatic 
melanoma, and nevi and metastatic melanoma. Differences were considered 
significant at p ≤ 0.05. Similar to IL-6, however, IGFBP3 transcript levels were not 
statistically different from one tissue type to another (Figure 9). 
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Figure 9. IGFBP-3 Box and Whisker Plot:  Box and Whisker plot comparing copy 
number ratios among the three types of tissues tested for IGFBP-3 gene expression. 
Statistical analysis is discussed in the text. Note that sample size (n) for each type of 
tissue was n = 9. Respective p-values are noted. The top of each green bar indicates the 
value of a maximum outlier.  
 
	    
Discussion 
  
From the analysis, we concluded that both genes do not show statistically 
significant difference in expression levels among nevi, primary and metastatic 
melanoma tissues. IL-6 shows no statistical difference between nevi and primary 
tissues (p = 0.159), primary and metastatic tissues (p = 0.465), and nevi and 
metastatic tissues (p = 0.141). Similarly, IGFBP-3 shows no difference between 
nevi and primary melanomas (p = 0.659), primary and metastatic melanomas (p 
= 0.283), and nevi and metastatic melanomas (p = 0.175).  
Sample size may have played a factor as to the why there was no statistically 
significant difference of gene expression levels among the three types of tissues. 
Nine nevi, nine primary, and nine metastatic melanoma tissue samples most 
p=0.659 
p=0.175 
p=0.283 
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likely are not representative of the respective melanoma populations, especially 
with so much heterogeneity among melanoma tumors.  It is entirely possible that 
a few of the tissue samples we have just do not express the genes that we are 
looking for. Thus, increasing the sample size to assess for gene expression 
would provide for a more statistically valid data set.  
 
Conclusion 
Although we did not get positive results from this study, it is still encouraging 
to see that IL-6 has almost no expression in nevi tissues, but is present in 
primary melanoma and metastatic melanoma samples. This demonstrates that 
IL-6 may be a gene worth studying further to provide more evidence for the idea 
that the immune system has a role in cancer progression. Studies with a larger 
sample size may produce a positive result and demonstrate a strong correlation 
between IL-6 and melanoma proving this gene may hold promise as a novel 
biomarker for melanoma.  
Future steps also include testing other genes for their presence in progressive 
melanoma. Chemokine (C-X-C motif) ligand 1 (CXCL1) is another gene of 
interest in our lab. This gene encodes a chemokine that is secreted by melanoma 
cells, and is thus also termed for its function: melanoma growth stimulating 
activity, alpha. CXCL1 serves as a chemo-attractant for neutrophils during the 
inflammatory process. Uncontrolled production of CXCL1, however, increases 
tumor angiogenesis and may play a role in cell migration and invasion when 
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studied in certain prostate cancers (Kuo 2247). Studies of ovarian and 
endometrial cancer cells showed that hormones such as progesterone reduce 
expression of CXCL1 resulting in a significant inhibition of cancer metastasis 
(Kavandi 3143).  
With melanoma incidence on a continual rise, public awareness and 
recognition of the risks and causes of this cancer is an advantageous method for 
decreasing this rate of incidence.  Simple campaigns aimed at protection from 
prolonged sun exposure or universal education regarding the ABCDE mnemonic 
is crucial, especially since the best cure for melanoma is early recognition and 
excision. Nonetheless, continual research into melanoma pathogenesis and 
consequent systemic effects are essential for the identification of biomarkers and 
production of drugs for treatment. Biomarkers truly hold the future for melanoma 
staging and prognosis, as demonstrated by the recent incorporation of serum 
LDH levels as a consideration for evaluating stage IV melanoma tumors. Each 
sub-stage of a melanocytic tumor holds a potential target for therapy and the goal 
of the melanoma community is to find those targets before a suspicious lesion 
becomes an invasive tumor.  
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